Skip to main content
Figure 5 | BMC Gastroenterology

Figure 5

From: Mucosal gene therapy using a pseudotyped lentivirus vector encoding murine interleukin-10 (mIL-10) suppresses the development and relapse of experimental murine colitis

Figure 5

Histopathology sections of DSS colitis treated with LV encoding mIL-10. Representative sections of each treatment groups are shown following DSS exposure at Day 10 (a, b, c, d) or Day 32 (e, f, g, h). Normal controls for each are shown in (a) and (e). Mock-treatment group showed the expected severe colonic inflammation on both Days 10 and 32. Treatment with LV encoding mIL-10, regardless of whether given once per DSS cycle (LV(1)) or twice/cycle (LF(2)), showed reduction in inflammation on both Days 10 and 32. (H & E stain; magnification: 200×).

Back to article page